Online Education

22HT00053 – A School Nurse’s Guide to Bleeding Disorders: Hemophilia

May 27, 2022

5:00 PM Eastern, May 27, 2024
The estimated time to complete this activity is 45 minutes.

This online learning activity aims to enable the learner to develop basic knowledge and skills regarding etiology, inheritance, severity, and treatment of hemophilia, recognition of hemophilia symptoms, and use of strategies to promote a safe and positive learning environment.

The activity is designed for school nurses, nurse practitioners, and other school personnel who require basic knowledge and skill to effectively practice and teach in schools attended by a student with hemophilia. This involves debunking common myths that persist about hemophilia and replacing those myths with factual information concerning the etiology, inheritance, severity, and treatment of hemophilia. It includes information on identifying prevalent locations and symptoms of bleeding in hemophilia. Finally, the activity reviews strategies that may be implemented in the school setting to promote a safe and positive learning environment for the student with hemophilia.

This accredited continuing education activity is designed for nurses and nurse practitioners who practice in schools attended by a student with hemophilia. It may also be helpful to teachers, physical education and sports coaches, administrators, guidance counselors, and other educators and healthcare professionals needing an introduction to school related considerations in hemophilia.

At the conclusion of this activity, the participants should be better able to:

• Dispel common misconceptions about hemophilia
• Review basic information about the etiology, inheritance, and severity of hemophilia
• Identify prevalent locations and symptoms of joint and muscle bleeding in hemophilia
• Describe hemophilia treatment strategies and medications utilized and avoided in hemophilia management
• Discuss guidelines for participation in physical activity and sports by persons with hemophilia
• Integrate reasonable accommodations in the school setting to promote a safe and positive learning environment for the student with hemophilia
• Explain the role of the Hemophilia Treatment Center as a resource for support for schools attended by a student with hemophilia

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 0.75 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Explorer
  • Cookies and JavaScript must be enabled in the browser

22HT00081 – A School Nurse’s Guide to Bleeding Disorders: von Willebrand Disease

December 22, 2022

5:00 PM Eastern, December 23, 2023
The estimated time to complete this activity is 30 minutes.

This activity aims to enable the learner to enhance his/her knowledge about von Willebrand disease (VWD), common treatment methods/products, and accommodations recommended to provide a safe and positive learning environment for the student with VWD.

A School Nurse's Guide to Bleeding Disorders: von Willebrand Disease contains information about von Willebrand disease (VWD), its treatment, and accommodations that must be made in order to promote a safe and positive learning environment for the student with VWD. This includes a definition of VWD and a description of common symptoms; description of VWD treatment; and exploration of the Hemophilia Treatment Center (HTC) comprehensive care team as an essential resource in managing the student with VWD.

This accredited continuing education activity is designed for professional school nurses in schools attended by a child with von Willebrand disease (VWD). Teachers, physical education instructors, school administrators, and guidance counselors. Other educators and healthcare professionals who require an introduction to school-related considerations for students with VWD.

At the conclusion of this activity, the participants should be better able to:

• Apply basic information related to the etiology and symptoms of von Willebrand disease (VWD) to clinical practice with students
• Recognize common treatments utilized for VWD within the school setting
• Integrate strategies in the school setting to promote a safe and positive learning environment

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 0.5 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Explorer
  • Cookies and JavaScript must be enabled in the browser

22HT57252 - Gene Therapy for Providers 101

October 14, 2022

5:00 PM Eastern, October 13, 2023
The estimated time to complete this enduring material is 45 minutes.

The purpose of this activity is to enable learners to develop basic knowledge of gene therapy for hemophilia, thereby enhancing learner competence to discuss gene therapy with patients who may benefit from this emerging treatment.

This learning activity provides basic education on hemophilia gene therapy, including the aims of gene therapy; the packaging, delivery, and activity of the replacement genes; and the means by which the replacement genes lead to production and/or availability of normal clotting factor in persons with hemophilia. The module will also review information that may be particularly important when discussing hemophilia gene therapy with patients, such as knowledgeable informed consent, outcomes data, and potential risks and benefits.

This accredited continuing education activity is designed for multidisciplinary providers at hemophilia treatment centers, including nurses, physicians, pharmacists, physical therapists, social workers, and genetic counselors providing care to persons with hemophilia A and hemophilia B.

At the conclusion of this activity, the participants should be better able to:

• Describe a pathway to preparedness for gene therapy from education of the multidisciplinary healthcare team to clinical delivery
• Provide an overview of the goal of gene therapy for hemophilia
• Explain the elements of gene therapy (i.e. packaging, administration, mechanism of action)
• Define the profile of gene therapy candidates with FVIII deficiency and FIX deficiency
• Review known adverse effects from completed and ongoing clinical trials
• Articulate critical considerations for the multidisciplinary healthcare team in providing care for patients receiving gene therapy
• Discuss issues related to obtaining knowledgeable informed consent and counseling patients

• Steven W. Pipe, MD
• Shelley Crary, MD, MSCS

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACISTS (PharmDs/RPhs)
The University of Nebraska Medical Center designates this activity for 0.75 ACPE contact hours. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion. UAN # JA0000319-9999-22-018-H01-P

NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 0.75 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

No commercial support was received for this activity.

If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Explorer
  • Cookies and JavaScript must be enabled in the browser

22HT57253 - Gene Therapy for Providers 201

October 14, 2022

5:00 PM Eastern, October 13, 2023
The estimated time to complete this activity is 60 minutes.

The purpose of this activity is to enable HTC multidisciplinary staff and institutional stakeholders to gain knowledge on the steps necessary to prepare an institution to administer AAV-mediated gene therapy for hemophilia.

This learning activity is a process-oriented intermediate course that will guide HTC staff through the steps an institution must take to prepare to administer hemophilia gene therapy upon commercial availability of these products.

This accredited continuing education activity is designed for HTC multidisciplinary staff (physicians, physician assistants, nurses, nurse practitioners, physical therapists, social workers, pharmacists, geneticists, genetic counselors, infusion room staff) and institutional stakeholders (e.g., HTC administrators and directors, clinic and pharmacy billing staff, insurance coordinators).

At the conclusion of this activity, the participants should be better able to:

• Identify patients who are eligible for AAV-mediated gene therapy
• Discuss key concepts involving education and shared decision-making for gene therapy
• Identify logistical/infrastructure requirements to procure, reconstitute and administer gene therapy at a dosing site
• Articulate the regional approach of preparing for gene therapy administration
• Distinguish the roles and responsibilities within the HTC team involved in the safety and efficacy assessments during short-and long-term monitoring before and after gene therapy
• Describe approaches to prevention, diagnosis, and treatment of vector-induced transaminitis after gene therapy

• Rebecca Kruse-Jarres, MD, MPH
• Ulrike Margret Reiss, MD
• Courtney Dawn Thornburg, MD, MS

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia and Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACISTS (PharmDs/RPhs)

The University of Nebraska Medical Center designates this activity for 1 ACPE contact hours. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion. UAN # JA0000319-9999-22-019-H01-P

NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 1.0 ANCC contact hour. Nurses should only claim credit for the actual time spent participating in the activity.

No commercial support was received for this activity.

If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Explorer
  • Cookies and JavaScript must be enabled in the browser

22HT57254 – Gene Therapy for Providers 301

October 14, 2022

5:00 PM Eastern, October 13, 2023
The estimated time to complete this enduring material is 60 minutes.

The purpose of this activity is to enable HTC multidisciplinary staff and hospital staff to support patients and their families as they consider hemophilia gene therapy, including education of patients and families on basic concepts in hemophilia gene therapy; administrative preparedness for providers; and short- and long-term care demands.

This learning activity is a process-oriented intermediate course that will guide HTC staff through the steps an institution must take to prepare to administer hemophilia gene therapy upon commercial availability of these products.

This accredited continuing education activity is designed for physicians, physician assistants, nurses, nurse practitioners, physical therapists, social workers, pharmacists, and infusion room staff.

At the conclusion of this activity, the participants should be better able to:

• Discuss introductory concepts in hemophilia gene therapy
• Outline the process of preparing patients, hemophilia treatment centers, and hospital systems for the administration of gene therapy
• Explain the steps necessary for multidisciplinary team members to engage in shared patient-centered and population focused problem solving when procuring a hemophilia gene therapy product, preparing the product, and infusing the patient safely
• Discuss short term monitoring, specifically immediately after infusion and during the first three months of follow up
• Discuss long term monitoring, specifically from 3 to 24 months post infusion and > 24 months post infusion

• Doris V. Quon, MD
• Lindsey A. George, MD

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACISTS (PharmDs/RPhs)
The University of Nebraska Medical Center designates this activity for 1 ACPE contact hours. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion. UAN # JA0000319-9999-22-020-H01-P 

NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 1.0 ANCC contact hour. Nurses should only claim credit for the actual time spent participating in the activity.

No commercial support was received for this activity.

If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Explorer
  • Cookies and JavaScript must be enabled in the browser

21HT50146 – Hereditary Hemorrhagic Telangiectasia: Right Under Your Nose

June 1, 2022

5:00 PM Eastern, May 31, 2024
The estimated time to complete this activity is 60 minutes.

This online learning activity aims to enable the learner to gain knowledge and expertise regarding hereditary hemorrhagic telangiectasia (HHT), including inheritance and pathophysiology, screening guidelines, management, and the importance of the multidisciplinary approach in caring for these patients.

This online learning activity provides a detailed introduction to hereditary hemorrhagic telangiectasia (HHT) appropriate for an audience of multidisciplinary health care providers involved in the team-based care of patients with HHT. This overview includes information on the genetic inheritance and pathophysiology of HHT as well as the widely-used Curaçao diagnostic criteria to determine if a person has HHT, consensus screening guidelines for HHT management, and an explanation of the importance of a multidisciplinary approach to care of patients with HHT. This activity incorporates case scenarios and interactive questions to encourage active learning through application of the content.

This accredited continuing education activity is designed for physicians, physician assistants, nurse practitioners, nurses, and other multidisciplinary team members who care for patients with hereditary hemorrhagic telangiectasia.

At the conclusion of this activity, the participants should be better able to:

• Identify the Curaçao criteria for determining the likelihood of Hereditary Hemorrhagic Telangiectasia (HHT) in an undiagnosed individual
• Describe HHT genetics and pathophysiology
• Discuss the international consensus screening guidelines for HHT management
• Review management of epistaxis, iron deficiency, and pulmonary arteriovenous malformations (PAVMs) in HHT
• Explain the importance of an HHT Center-driven multidisciplinary approach in caring for patients with HHT

• Manjusha Kumar, MD
• Magdalena Lewandowska, MD

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 1.0 ANCC contact hours. This activity is provided for 0.15 contact hours related to pharmacotherapeutic content. Nurses should only claim credit for the actual time spent participating in the activity.

No commercial support was received for this activity.

If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Explorer
  • Cookies and JavaScript must be enabled in the browser

22HT00069 – Is That Ok? Ethical Dilemmas In Our Community

October 20, 2022

5:00 PM Eastern, October 21, 2024
The estimated time to complete this activity is 30 minutes.

The purpose of this online learning activity is to enable the learner to enhance competencies to recognize ethical dilemmas, identify the relevant ethical concepts and principles, and apply the ethical decision-making process to resolve these dilemmas.

This online learning activity provides healthcare professionals and others an opportunity to gain knowledge about ethical theories, key ethical concepts, and the opportunity to apply these theories and concepts through case study examples.

This accredited continuing education activity is designed for members of the hemophilia treatment center (HTC) multidisciplinary comprehensive care team including Nurses and Social Workers.

At the conclusion of this activity, the participants should be better able to:

• Define ethics and the essential questions underlying ethical theories
• Distinguish four settings in which ethics and ethical action are ongoing considerations
• Interpret key ethical principles and the ethical decision-making process
• Identify relevant ethical principles in common ethical dilemmas encountered by persons with bleeding disorders and their providers

• Kristie Ostash, MD
• Sabrina Farina, LMSW
• Jim Munn, MS, BS, BSN, RN-BC

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 0.5 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Explorer
  • Cookies and JavaScript must be enabled in the browser

September 15, 2023

5:00 PM Eastern,September 15, 2025 
The estimated time to complete this activity is 60 minutes.

The purpose of this activity is to enable the learner to address the burden of reduced quality of life that has been documented among persons and families with hemophilia with an inhibitor. This module describes various validated quality of life instruments and patient testimonials to provide insight into differences in both the physical and mental health-related quality of life domains for persons with hemophilia with an inhibitor and their parents/caregivers versus persons with hemophilia without an inhibitor. Highlighting how living with an inhibitor compromises quality of life, the module offers strategies for effective psychosocial interventions to address these issues in persons with hemophilia with an inhibitor and their caregivers and family members. Social workers, nurses, and other healthcare professionals involved in the management of persons with hemophilia with an inhibitor will benefit by learning more about interventions to address reduced quality of life and how to implement such strategies. 

The module reviews studies using a variety of validated quality of life instruments to provide insight into differences in both the physical and mental health domains for persons with hemophilia with an inhibitor and their parents/caregivers versus persons with hemophilia without an inhibitor. The module also discusses the differences in health-related quality of life among persons with an inhibitor based on treatment frequency, age, and adherence. It also covers the impact of inhibitors on quality of life of parents/caregivers of persons with hemophilia with an inhibitor, describes a real-time study of health-related quality of life differences on bleed vs nonbleed days, and describes the effect of prophylaxis on persons with an inhibitor. The module concludes with an overview of various strategies to psychosocial interventions in persons with an inhibitor. 

This accredited continuing education activity is designed for psychosocial professionals, nurses, nurse practitioners, and other members of the health care team who are involved in the care of individuals with congenital hemophilia who have an inhibitor to clotting factor VIII or IX. 

At the conclusion of this activity, the participants should be better able to:

• Explain the basic pathophysiology of an inhibitor in hemophilia 
• Describe the psychosocial, physical, and financial impact of an inhibitor in persons with hemophilia and their families 
• Recount differences in physical and mental health-related quality of life domains for persons with hemophilia with an inhibitor versus persons with hemophilia without an inhibitor.
• Identify differences in quality of life for parents/caregivers of persons with hemophilia with an inhibitor versus parents/caregivers of persons with hemophilia without an inhibitor 
• Compare differences in quality of life among persons with hemophilia with an inhibitor on bleed and nonbleed days 
• Describe differences in quality of life for the physical and psychosocial domains for persons with hemophilia with an inhibitor on prophylaxis versus those receiving on-demand treatment 
• Discuss the roles/responsibilities of the healthcare team when utilizing psychosocial interventions and other communication techniques when caring for persons with hemophilia with an inhibitor 

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 80% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 1.0 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

As a Jointly Accredited Organization, University of Nebraska Medical Center is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1.0 clinical continuing.

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.  

If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Explorer
  • Cookies and JavaScript must be enabled in the browser

August 29, 2023

5:00 PM Eastern, August 29, 2025 
The estimated time to complete this activity is 75 minutes.

The purpose of this activity is to enable learners to provide competent psychosocial support to persons with hemophilia (PWH) as they navigate changes associated with the aging process. 

This activity will describe the increasing burden of chronic disease in elderly Americans and the role of extended life expectancy on prevalence of chronic conditions among elderly persons with hemophilia. The activity assesses psychosocial considerations in managing care for elderly persons with hemophilia and recommends practical assessment strategies for use in the Hemophilia Treatment Center environment to optimize care of these individuals. 

This accredited continuing education activity is designed for social workers, nurses, and other members of the multidisciplinary comprehensive care team at U.S. federally-recognized hemophilia treatment centers (HTCs) who routinely encounter adult persons with hemophilia (PWH) in need of support to navigate changes associated with the aging process.

At the conclusion of this activity, the participants should be better able to:

• Describe the increasing burden of chronic disease among persons aged 65 and over in the United States 
• Review the evolution of hemophilia treatment and the associated increase in life expectancy among persons with hemophilia 
• Evaluate the prevalence of chronic conditions among aging and elderly persons with hemophilia 
• Assess psychosocial considerations pertinent to the care of aging and elderly persons with hemophilia 
• Incorporate practical psychosocial assessment strategies in the hemophilia treatment center environment to optimize care of aging and elderly persons with hemophilia 

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 80% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 1.25 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

As a Jointly Accredited Organization, University of Nebraska Medical Center is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1.25 clinical continuing.

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.  

If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Explorer
  • Cookies and JavaScript must be enabled in the browser